- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alligator Bioscience AB (ATORX)
Alligator Bioscience AB stock price live, this page displays ST ATORX stock exchange data. View the ATORX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alligator Bioscience AB real time stock price chart below.
What Is the Alligator Bioscience AB Stock Price Today?
The Alligator Bioscience AB stock price today is 0.2105.
What Is the Stock Symbol for Alligator Bioscience AB?
The stock symbol for Alligator Bioscience AB is "ATORX."
What Stock Exchange Does Alligator Bioscience AB Trade On?
Alligator Bioscience AB is listed and trades on the Stockholm stock exchange.
Is Alligator Bioscience AB a Good Stock to Buy?
Determining whether Alligator Bioscience AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATORX quote. (ISIN: SE0024173637)
What Is the Alligator Bioscience AB Stock Price Today?
The Alligator Bioscience AB stock price today is 0.2105.
What Is the Stock Symbol for Alligator Bioscience AB?
The stock symbol for Alligator Bioscience AB is "ATORX."
What Stock Exchange Does Alligator Bioscience AB Trade On?
Alligator Bioscience AB is listed and trades on the Stockholm stock exchange.
Is Alligator Bioscience AB a Good Stock to Buy?
Determining whether Alligator Bioscience AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATORX quote. (ISIN: SE0024173637)
0.2105
+0.0010(+0.48%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2040
0.2160
52 wk Range
0.1570
7.2100
ATORX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.20400.2160
52 wk Range
0.15707.2100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATORX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Alligator Bioscience AB Earnings Call Summary for Q1/2026
- Alligator Bioscience slashed annual operating costs from SEK 300M to SEK 100M, ending Q1 2026 with SEK 33M cash and runway through mid-Q3 2026.
- Lead asset Mitazalimab showed 20% 30-month survival rate in Phase II; Phase III trial initiation planned for Q4 2026 with Q2 regulatory submissions.
- Stock rose 4.69% post-earnings despite 95% annual decline; market cap stands at $15M with company exploring urgent financing options to continue operations.
- Generated SEK 90M from TO 14 warrant exercises; potential HLX22 revenues projected from 2030, exploring expansion beyond pancreatic to biliary tract cancer.
Last Updated: 05/05/2026, 07:48 PM
Read Full TranscriptEarnings
Latest Release
May 05, 2026
EPS / Forecast
-- / --
Revenue / Forecast
98K / --
Compare ATORX to Peers and Sector
Metrics to compare | ATORX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATORXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.2x | −3.5x | −0.5x | |
PEG Ratio | −0.03 | 0.08 | 0.00 | |
Price/Book | 3.2x | 3.8x | 2.6x | |
Price / LTM Sales | 253.1x | 11.3x | 3.1x | |
Upside (Analyst Target) | 38.6% | 123.1% | 54.0% | |
Fair Value Upside | Unlock | 0.0% | 6.5% | Unlock |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 2 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers; and HLX22, an antibody that treats metastatic, gastric, and breast cancers, which is in phase 3 clinical trial. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; Henlius Biotech, Inc.; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alligator Bioscience (ATORX) Stock Price Today?
The Alligator Bioscience stock price today is 0.2105 SEK.
What Stock Exchange Does Alligator Bioscience Trade On?
Alligator Bioscience is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Alligator Bioscience?
The stock symbol for Alligator Bioscience is "ATORX."
What Is the Alligator Bioscience Market Cap?
As of today, Alligator Bioscience market cap is 132.2200M SEK.
What Is Alligator Bioscience's Earnings Per Share (TTM)?
The Alligator Bioscience EPS (TTM) is -0.2580.
When Is the Next Alligator Bioscience Earnings Date?
Alligator Bioscience will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is ATORX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Alligator Bioscience Stock Split?
Alligator Bioscience has split 2 times.
How Many Employees Does Alligator Bioscience Have?
Alligator Bioscience has 11 employees.
What is the current trading status of Alligator Bioscience (ATORX)?
As of May 21, 2026, Alligator Bioscience (ATORX) is trading at a price of 0.2105 SEK, with a previous close of 0.2095 SEK. The stock has fluctuated within a day range of 0.2040 SEK to 0.2160 SEK, while its 52-week range spans from 0.1570 SEK to 7.2100 SEK.
What Is Alligator Bioscience (ATORX) Price Target According to Analysts?
The average 12-month price target for Alligator Bioscience is 0.3000 SEK, with a high estimate of 0.3 SEK and a low estimate of 0.3 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +42.52% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.